Lung-Ji Chang OCM

HIV-Prevention Research


          Scientific Federation cordially inviting you to attend the 2nd International Conference & Expo on HIV-AIDS-2018 which will be held in Toronto, Canada during September 17-18,2018. This year we focused on the Theme of ACCELERATING ADVANCEMENTS IN HIV-AIDS TO THE GLOBE.

                         

          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynaecology, Global Health, and Population Health.

Major Session on Conference in HIV&AIDS-2018 is Prevention Research and Interventions for Persons Living with HIV/AIDS:

          Description:  The National Institutes of Health, the Centres for Disease Control and Prevention, and the HIV/AIDS Bureau of the Health Resources and Services Administration support the CDC's Serostatus Approach to Fighting the HIV Epidemic. One aim of the strategy is to help individuals living with HIV adopt and sustain HIV and STD risk reduction, treatment adherence, and effective strategies for coping with HIV/AIDS. Efficacious interventions are needed by community organizations and clinics that provide evidence-based services. To expedite translation from research to practice, we convened scientist-practitioners, HIV treatment and prevention providers, and community/consumer members.



          Definition: The World Health Organization guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Qualitative data was sort of health care providers working at the public family planning clinic and other key informants working with young women. They were identified by the study staff using local networks to document perspectives on factors influencing young women’s decisions to take up and adhere to PrEP as an HIV prevention strategy.  Textual data coding as a primary qualitative analytical approach was used to summarize, extract meaning and condense the data using Nvivo.

          Research Information: HIV is the leading cause of death among adolescents aged 10–19 in sub-Saharan Africa and the second most common cause of death among adolescents globally, yet this population is not significantly targeted for HIV research. Consequently, there is a dearth of appropriate evidence-based interventions that expressly focus on their HIV needs and the stages of their development. Despite the advances made in HIV prevention, care, and treatment worldwide, adolescents are the only population whose death rates from AIDS are not declining in sub-Saharan Africa. The majority of these deaths occur among adolescents who were infected at birth and infancy. Access to and uptake of HIV testing and counseling among adolescents in sub-Saharan Africa is significantly lower compared to adults, and antiretroviral therapy coverage rates for adolescents living with HIV are also significantly lower compared to other populations living with HIV. This signals the need for deliberate, appropriate, and targeted adolescent HIV programs if the tide of adolescent deaths from AIDS is to be stemmed. Many of the previously implemented HIV prevention interventions for adolescents failed. This is because they did not focus on the factors critical to adolescent development. Integrating developmental factors into the overall context in which HIV transmission occurs is critical to building strong and appropriate HIV prevention interventions that work for adolescents.

          Current Research: Current treatment for HIV/AIDS with highly active antiretroviral therapy can be effective but often associated with numerous side effects yet still without a cure. Extensive efforts have been poured into the clearance of the hidden viral reservoir and eliciting immune resistance to HIV. Lent viral anti-HIV hematopoietic stem cell gene therapy offers a potential final solution to this endeavor. We have developed an anti-HIV stem cell gene therapy strategy based on the combination of an advanced lent vector system and multiple anti-HIV genes. A novel lent vector has been established that can simultaneously express microRNA to block endogenous CCR5 expression, a sequence-modified CCR5Δ32 gene to interfere with the function of native CCR5, and multiple selected anti-HIV shRNAs to target viral RNAs.  In vitro assays demonstrated that ectopic expression of CCR5Δ32 protected against R5-HIV-1 infection. In addition, the expression of a CCR5 miRNA effectively blocked R5-HIV-1 infection. The further addition of an intronic cassette incorporating miRNAs targeting three viral RNA sites including HIV-1 pol, int, and vpu, had shown marked anti-HIV effects. Evidence supports that transduction of adult CD34+ hematopoietic stem cells with this anti-HIV multi-gene vector does not impair hemopoiesis of the HSCs. Thus, autologous HSC transplantation to ectopically express CCR5Δ32 and multiple miRNAs targeting endogenous CCR5 and three highly conserved HIV-1 genomic sites may provide an ultimate cure to end HIV-1/AIDS.




To Know More about Hiv-Aids-2018: Click Here 
Continue Reading

Keynote Speakers

HIV-AIDS
                       
          Scientific Federation cordially inviting you to attend the 2nd International Conference & Expo on HIV-AIDS-2018 which will be held in Toronto, Canada during September 17-18,2018. This year we focused on the Theme of ACCELERATING ADVANCEMENTS IN HIV-AIDS TO THE GLOBE.

Scientific Sessions:
  • Clinical Research
  • HIV Revolution
  • Epidemiology and Prevention Research
  • Advances in systems and synergies with other Health and Development Sectors
  • HIV Incidence Surveillance
  • HIV Case Surveillance
  • Prevention Research and Interventions for Persons Living with HIV/AIDS
  • Advances in HIV Testing Technology
  • HIV Program Planning and Evaluation
  • HIV Testing Programs in Health Care and Non-Health Care Settings
  • Biomedical and Behavior Prevention Programs
  • HIV Community Planning & Participatory Approaches to HIV Prevention
  • HIV-Related Policy, Economics, and Program Integration
  • Structural, Policy, and Environmental Interventions.

          Conference sessions will bring you the latest strategies, research, and best practices to improve outcomes through quality, safety, and staffing. Attendees will learn from evidence-based research and discover innovations they can start using immediately. Join your peers at a conference for focusing on quality outcomes.

Keynote Speakers:
     1) Hiroshi Ohrui:
       Title of Presentation: EFdA: An Extremely Excellent Anti-HIV Nucleosides,-How it was developed, and the clinical results.
          Prof. Hiroshi Ohrui received Ph. D. degree from The University of Tokyo.                     
            He Joined RIKEN and moved to Tohoku University. He moved to the Yokohama University of Pharmacy.
         He worked for Dr. J. J. Fox at Sloan-Kettering Institute for Cancer Research (1972-1973) and for Dr. J. G. Moffatt at Syntex Research (1973-1974).
            He received several awards including Inoue Prize for Science (1991), Japan Prize for Agricultural Sciences (2004), The Japan Society for Analytical Chemistry Award (2004), and Japan Academy Prize (2001). His research interests cover Organic Synthesis, Chemical Biology, and Chiral Discrimination.

     2) Saeed Bayanolhagh:
          Title of Presentation: Challenges and obstacles of HIV detection based on new algorithms.
          Dr. Saeed Bayanolhagh was Head of Iranian HIV research center. He established an HIV/AIDS basic science laboratory that performs testing for a full range of HIV/AIDS diagnosis tests and research projects in Iranian HIV research center in Imam Hospital in heart of Tehran, Iran. Saeed has 15 years’ experience in HIV research fields. Previously he worked as a scientific adviser at Iranian cell culture producer, Gooya Innovative Biotech Company. He was also head of HIV detection group in ELISA and Chemiluminescence department in Pouya Zist tech Company, Tehran, Iran previously. He worked as Quality Control manager in HIV diagnosis assay department at Biotechnology development center Pasteur Institute of Iran for 10 years. Saeed has research interests in HIV basic science researchers especially HIV Vaccines, HIV diagnosis methods, Immuno - viral interaction and Immunopathogenesis.

     3) J. Anitha Menon:
          Title of Presentation: Dilemma on disclosing or not disclosing HIV status- A qualitative analysis of perceived experiences from Lusaka, Zambia.
           Prof. Anitha Menon is a faculty member in the Department of Psychology, University of Zambia and the Chairperson for the University of Zambia Committee on HIV and AIDS. She is also the President of the Psychology Association of Zambia
. She holds Ph.D. in Health Psychology from University of Nottingham, UK. For more than 20 years Prof. Menon has been actively involved in various researches and service related projects pertaining to areas on public interest, her major research interest pertains to the issue of HIV and well-being and psychological well-being of adolescents, Neuropsychological Challenges of HIV, Sexual Harassment and Communication Skills of Health Practitioners. She has several publications on various national and international journals and has been featured in various media reports. She was the recipient of the award for the Best Professor in Psychology from World Education Congress (2012) and the Change Fellowship (2012), received the ‘Women Leadership Achievement Award’ from Women’s Leadership Congress (2014), the Labor Day Award from University of Zambia for Innovation and Excellence in May 2014, Most Influential Woman in Education and Training sector from CEO global -Country and Regional Awards (September 2017), Continental Award (November 2017).



          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.

To Know More about Hiv-Aids-2018: Click Here
Continue Reading

People Living with HIV in UK

HIV Testing Programs


                        
         
          Scientific Federation proudly invites all the participants from all over the world to attend 2nd International Conference & Expo on HIV & AIDS during Sep 17-18, 2018 in Toronto, Canada.

           According to the 2011 census, there were 989,628 people of black African background in England and Wales. 479,799 were men and 509,829 were women. The population of black African represents about 1.8% of the resident population of England. The Public Health of England situational report of 2015 on HIV indicated that the number of people living with HIV in the UK continues to increase and the number living with undiagnosed HIV remains high. It was estimated that 103700 people were living with HIV in the UK in 2015, of which about 17% were undiagnosed and did not know about their HIV status. The report also showed that about 40% of people diagnosed with HIV in 2015 were diagnosed late. The number of people living with HIV aged over 50 has been increasing and there has been a 2% decrease in testing at sexual health clinics over the past year. The report indicated that 54,100 people had acquired HIV through heterosexual sex. More than one in five was unaware of their HIV infection. A higher proportion of those diagnosed with HIV was living outside London. It is a fact that if someone has a late diagnosis, it is more likely that the virus will have already seriously damaged his or her immune system. 51% black African suffered in this way according to PHE 2014 statistics.

          Across Luton, HIV rates among men who have sex with other men (MSM) as well as heterosexual black African men and women continue to go up. In Luton there are 622 Luton residents that are HIV positive accessing care, of which 470 are seen and treated in Luton, 409 are of Black African origin (PHE, 2016). I am an enthusiastic and a staunched member of a black African and Caribbean Church as are many of my fellow countrymen. The leading Pastor is a very influential figure in these communities. His role is pivotal in encouraging HIV/AIDS patients to take prescribed medications as well as participating in prayer. Sadly, the recent investigation by health agencies and the media exposed major concerns that some Pastors are advising their church members not to take an HIV test and to refrain from taking anti-retroviral therapy (ART) or Pre-Exposure Prophylaxis (PrEP). Some Pastors prefer to teach that prayer alone will provide a cure. Those who adhered to this ignorant approach were not well served by their Pastors. In 2011, the BBC reported that Evangelical Christians Pastors claims that prayer alone could cure HIV/AIDS caused three deaths.

          To make matters worse, a significant number of infections remain undiagnosed, which once again underlines the importance of testing. Black African men and women are advised to have an HIV test and a regular HIV and sexually transmitted infections (STI) screen if having unprotected sex with new or casual partners. However, the uptake in HIV testing remains relatively low, partly because of complacency about HIV/AIDS as a major global health concern, but also because of the age-old stigma around the virus that we haven’t yet managed to completely shake. While diseases like cancer are addressed and discussed openly, HIV is often a topic that people avoid talking about it*956, which leads to a culture of shame and misinformation. Many are so afraid of contracting HIV that they avoid testing, choosing not to know their status. Many are too afraid to tell their partners that they are HIV positive, in case they are rejected and shamed. HIV is a virus. It doesn’t define anyone and doesn’t contribute or take away anything from an individual’s worth. It is a health problem that we all need to discuss and tackle together.

          Research evidence suggested that the stigma and the discrimination associated with HIV are serious burdens for many black African people living with HIV in the UK. A national strategy is needed to address HIV- related stigma, including within the NHS, and this should also be reflected in local initiatives, especially in areas of high HIV prevalence. It is really important to adopt effective anti-stigma approaches to include improved information on HIV treatment and prognosis, engagement with faith communities in anti-stigma and anti-discrimination work, as well as addressing wider racism associated with HIV.

          In fact, there is a need for an expanded and a scaled up HIV testing programmes across the target communities to reduce undiagnosed infection and late diagnosis. It is very important that HIV is diagnosed early so that people can start treatment, look after their own health and take steps to ensure that they don’t pass the virus on. Delay in diagnosis increases the risk of complications and death. Most people living with HIV infection if diagnosed early can be well managed and lead full and healthy lives. Early testing and diagnosis of HIV reduce treatment costs: £12,600 per annum per patient, compared with £23,442 with a later diagnosis (PHE, 2015).

          Take Action Now and U Test 4 Life project was designed to aim at reducing new infection rate of HIV and promoting early diagnosis through setting up testing clinic in the high risk communities, promoting and creating awareness of HIV /AIDS, challenging the stigma and discrimination associated with HIV /AIDS in churches and communities through mass campaign and education, signposting people to various GUM Clinics and other HIV Support services in the community for effective treatment and medication, increasing capacity building of services and treatment to people living with HIV and their families in the high risk communities in Luton. It took place in the high-risk communities in Luton -Bedfordshire in the East of England where the majority of the black African people are populated especially in the High Town ward of Luton. The High Town community is considered as red light zones because the HIV infection is high due to women indulge in the sex trade, men have sex with men, people engage in drugs due to poverty.

          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.

To Know More about Hiv-Aids-2018: Click Here
Continue Reading

Prof. Nassiri as an OCM in our Conference

HIV Community & Planning



                        
          Scientific Federation proudly invites all the participants from all over the world to attend 2nd International Conference & Expo on HIV & AIDS during Sep 17-18, 2018 in Toronto, Canada.

          Prof. Nassiri is an OCM in our Conference and he is a former Associate Dean of Global Health at the Michigan State University (MSU).  He also served as MSU director of Institute of International Health.  He is currently a faculty member of the departments of Pharmacology and Toxicology, and, Family and Community Medicine, and, lecturer in Global Health, Infectious Diseases, and Tropical Medicine.  He currently works on international public health issues relating to chronic diseases and has expertise in global health. He has made contributions in various fields of medical sciences including clinical investigation and health education. On the basis of his extensive experience and expertise in chronic infectious diseases including HIV/AIDS, TB as well as antimicrobial resistance and human gut microbiome, he developed clinical research programs in Brazil, South Africa, Haiti, Dominican Republic and Mexico. He had served as editorial board member for the Journal of HIV and AIDS Review.  He is currently an editorial board member for AIDS Patient Care and STDs, and International Journal of Global Health.  Prof. Nassiri has delivered seminar presentations on Tropical Medicine, HIV/AIDS, TB, Global Health and public health interventions in numerous national and international conferences and workshops. He is internationally recognized for his work in the areas of building effective international partnerships particularly in global health, community health, clinical care capacity building, and technical assistance mechanism. He has developed academic and research partnership programs with Federal University of Para Institute of Tropical Medicine in Belem, Brazil.

          AIDS remains a public health and social challenge threatening the global population.  There are approximately 36.5 million people currently living with HIV and tens of millions of people have died of AIDS-related complications since the beginning of the epidemic. The greatest prevalence and incidence remains in Eastern and southern Africa with 19 million (52%) affected.  While new cases have been reported in all regions of the world, approximately two-thirds are in sub-Saharan Africa, with 46% of new cases in Eastern and Southern Africa.  In the endemic regions outside the western countries, many people living with HIV or at risk for HIV do not have access to prevention, care, and treatment.  HIV impacts households, communities, and the development and economic growth of nations.

          The number of HIV-positive patients receiving treatment has increased to more than 18 million in 2016.  However, significant gaps exist.  While studies show declines in new infections among adults observed earlier in the epidemic, the incidence is now rising particularly in China and India.  HIV epidemic has led to a resurgence of tuberculosis (TB), particularly in Africa.  TB is a leading cause of death for people with HIV worldwide.  In 2015, approximately 11% of new TB cases occurred in people living with HIV.  Interestingly, between 2004 and 2014 TB deaths in people living with HIV declined by 32%, largely due to the scale-up of joint HIV/TB services (The Global HIV/AIDS Epidemic, Kaiser Family Foundation.  January 2017). 

          From our experience of HIV preventive work in the Dominican Republic, effective prevention strategies include behavior change programs, condom use, HIV testing, blood supply safety, harm reduction efforts for injecting drug users, and male circumcision (WHO and CDC recommendations). Additionally, recent research has shown that providing HIV treatment to people with HIV significantly reduces the risk of transmission to their HIV-negative partners. Pre-exposure antiretroviral prophylaxis (PrEP) has also been shown to be an effective HIV prevention strategy in individuals at high risk for HIV infection.  In 2015, the WHO recommended PrEP as a form of prevention for high-risk individuals in combination with other prevention methods.  Additionally, in 2016, the U.N. Political Declaration on HIV/AIDS stated PrEP research and development should be accelerated.  Numerous studies suggest that prevention should be based upon “evidenced-based knowledge of epidemic” directed to tailor the prevention and control measures to the local context and epidemiology, and using a combination of sustainable strategies.  However, access to prevention remains limited especially in resource-limited counties, and there have been renewed calls for the strengthening of prevention efforts. 

          In the United States, new HIV infections are becoming rare.  When they do occur, every person, regardless of age, gender, race/ethnicity, sexual orientation, gender identity, or socio-economic circumstance, will have access to quality, life-extending care, free from stigma and discrimination.  The goals of the US national HIV/AIDS prevention and control strategies are to reduce new HIV infections, to allow increased access to care and improved outcomes among People Living with HIV, to reduce HIV-related disparities and health inequities among the minority and migrant populations, and to achieve a more coordinated HIV national response (National HIV/AIDS Strategy, the White House, July 2012). 

          The Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia has dramatically impacted the regional response to the epidemic. The monitoring process of the Declaration has provided valuable insight on the progress of HIV prevention and control by countries and where improvements in national programs must be made to reduce the number of new infections and improve the quality of life for people living with HIV.  

          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
To Know More about Hiv-Aids-2018: Click Here
Continue Reading

Pre-exposure prophylaxis (PrEP)




HIV Prevention


        


          Scientific Federation proudly invites all the participants from all over the world to attend 2nd International Conference & Expo on HIV & AIDS during Sep 17-18, 2018 in Toronto, Canada.

          In recent research, it found that ageist stereotypes that lead to discrimination and prejudice against older people later it occurs frequently in young and can be seen in children at the age of 3. The most important factor associated ageist stereotypes was the poor quality of contact with grandparents. To assess aspects of ageism the youth were primarily white from urban and rural areas, and from a range of socioeconomic statuses. They also collected information from the youths.

          The World Health Organization (WHO) guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis (PrEP) for HIV. Qualitative data was sort of health care providers working at the public family planning clinic and other key informants (KIs) working with young women. They were identified by the study staff using local networks to document perspectives on factors influencing young women’s decisions to take up and adhere to PrEP as an HIV prevention strategy.  Textual data coding as a primary qualitative analytical approach was used to summarize, extract meaning and condense the data using Nvivo.

          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.

To Know More about Hiv-Aids-2018: Click Here
Continue Reading

HIV Revolution on EFDA



HIV REVOLUTION






          Hiv­-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.

          In the recent study, an injectable antiretroviral therapy (ART) contains 2 drugs Rilpivirine and Cabotegravir it has to administrate for every 4 or 8 weeks may be as effective as a daily oral dose of the drug in maintaining viral suppression in patients with HIV.

          The Introduction of a single tablet in ART dosing it’s represented a leap forward and it can be long-acting it may represent the next revolution in HIV therapy.

          DR. Hiroshi Ohrui the Professor of the Yokohama University of Pharmacy. He explained about An Extremely Excellent Anti-HIV Nucleosides, 4-C-Ethynyl-2-fluoro-2-deoxyadenosine (EFDA) has attached much attention due to its extremely excellent anti-HIV activity, for example EFDA prevents the emergence of resistant HIV mutants and is over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitory 2’,3’-dideoxy-nucleosides drug, very low toxic, very long-acting, very useful for the prevention of HIV-Infection.
For the design of the modified nucleoside which could solve the problems that the clinical drugs have (1. emergence of drug-resistant HIV mutants, 2. The adverse effect of drugs, 3. The necessity to take quite a few amounts of drugs), the following working hypotheses were proposed. They are (1) the way to prevent the emergence of drug-resistant HIV mutants, (2) the way to decrease the toxicity of modified nucleosides, (3) the way to provide the modified nucleoside with stability to both enzymatic and acidic glycolysis for long-acting.

          HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
To Know More about Hiv-Aids-2018: Click Here
Continue Reading

EPIDEMIOLOGY AND PREVENTION RESEARCH

                     

                                    EPIDEMIOLOGY AND PREVENTION RESEARCH

         



          Hiv­-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.

          The epidemiological context describes whether such risk reduction translates into Measurement of variables describing the epidemiological context, a measurable impact on HIV incidence can be used to tell the local suitability of interventions, The use in the transfer of a successful intervention from one context to another and in scaling up the effort to control HIV infection is explored and These indicators should provide a useful resource for those involved in planning HIV prevention interventions.

          The importance of different levels of indicators, corresponding to programme input, output, outcome, and impact, for the monitoring and evaluation of national HIV/AIDS programmes has recently been clarified. Which are the immediate biological and behavioral determinants of HIV spread, in other words the components of the basic reproductive rate, the efficiency The new method implemented by WHO and UNAIDS is preparing the latest country-specific HIV fact sheets ,WHO and UNAIDS organizations include indicators for proximate determinants, such as  self-reported sexual behavior which includes, non-regular sexual partnerships and context and outcome indicators, age at first sexual encounters, such as condom availability, knowledge of methods of HIV protection, general health service indicators for accessibility and blood safety.

          Of transmission, the rate of exposure of a susceptible to an infectious person, and the duration of infectiousness. It is through these proximate determinants that the impact of the broader socioeconomic context and the output of interventions on HIV incidence are seen.

          HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
To Know More about Hiv-Aids-2018: Click Here
Continue Reading
Subscribe to: Posts (Atom)